drugset / Trial / NCT01103440
Aspirin Resistance and Percutaneous Coronary Intervention (PCI)
RandomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study is to evaluate if aggressive antiplatelet therapy would reduce ischemic events in aspirin (ASA) resistant patients after percutaneous coronary intervention (PCI).
Timeline
- Start
- 2007-04
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Abciximab | Monoclonal antibody | — | Intravenous |
| Comparator | Cangrelor | Small molecule | — | Intravenous |
| Subject | Clopidogrel | Small molecule | 600 mg | — |
| Comparator | Eptifibatide | Other / unclassified | — | Intravenous |
| Comparator | Tirofiban | Other / unclassified | — | Intravenous |
| Background | Aspirin | Small molecule | 325 mg | Oral |
| Background | Prasugrel | Small molecule | — | — |
| Background | ticlopidine | Small molecule | — | — |
Indications
No indication recorded.